JP2021514400A5 - - Google Patents
Info
- Publication number
- JP2021514400A5 JP2021514400A5 JP2020566548A JP2020566548A JP2021514400A5 JP 2021514400 A5 JP2021514400 A5 JP 2021514400A5 JP 2020566548 A JP2020566548 A JP 2020566548A JP 2020566548 A JP2020566548 A JP 2020566548A JP 2021514400 A5 JP2021514400 A5 JP 2021514400A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- membered
- heteroaryl
- heteroatoms selected
- heterocyclyl
- Prior art date
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862632819P | 2018-02-20 | 2018-02-20 | |
| US62/632,819 | 2018-02-20 | ||
| US201862744086P | 2018-10-10 | 2018-10-10 | |
| US62/744,086 | 2018-10-10 | ||
| PCT/US2019/018773 WO2019164948A1 (en) | 2018-02-20 | 2019-02-20 | Inhibitors of egfr and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021514400A JP2021514400A (ja) | 2021-06-10 |
| JPWO2019164948A5 JPWO2019164948A5 (https=) | 2022-02-25 |
| JP2021514400A5 true JP2021514400A5 (https=) | 2022-02-25 |
Family
ID=67687390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566548A Pending JP2021514400A (ja) | 2018-02-20 | 2019-02-20 | Ｅｇｆｒの阻害剤およびその使用法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20200390783A1 (https=) |
| EP (1) | EP3755690A4 (https=) |
| JP (1) | JP2021514400A (https=) |
| AU (1) | AU2019225806A1 (https=) |
| CA (1) | CA3087288A1 (https=) |
| WO (1) | WO2019164948A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3755689B1 (en) | 2018-02-20 | 2023-12-06 | Dana-Farber Cancer Institute, Inc. | Inhibitors of egfr and methods of use thereof |
| CN119317636A (zh) * | 2023-03-07 | 2025-01-14 | 艾博生物科技(上海)有限公司 | 编码活化EGFR突变肽的免疫调节治疗性mRNA组合物 |
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040254159A1 (en) * | 2003-02-27 | 2004-12-16 | Hasvold Lisa A. | Heterocyclic kinase inhibitors |
| WO2006061126A2 (en) * | 2004-12-09 | 2006-06-15 | F. Hoffmann-La Roche Ag | Dibenzoxazepinone derivatives |
| US20070105835A1 (en) * | 2005-11-07 | 2007-05-10 | Kazantsev Aleksey G | Compositions and methods for modulating poly(ADP-ribose) polymerase activity |
| US20110028458A1 (en) * | 2008-04-11 | 2011-02-03 | Thallion Pharmaceuticals Inc. | Inhibition of cell migration by a farnesylated dibenzodiazepinone |
| CA2746220A1 (en) * | 2008-12-08 | 2010-07-08 | Vm Pharma Llc | Compositions of protein receptor tyrosine kinase inhibitors |
| EP2379559B1 (en) * | 2009-01-06 | 2017-10-25 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
| WO2012045194A1 (en) * | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Benzodiazepinones as fak inhibitors for treatment of cancer |
| WO2014160430A1 (en) * | 2013-03-13 | 2014-10-02 | Georgetown University | Small molecule lrrk2 and erk5 inhibitors |
| US20170114323A1 (en) * | 2014-06-19 | 2017-04-27 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| WO2017024317A2 (en) * | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| US11155556B2 (en) * | 2016-04-07 | 2021-10-26 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and methods for treating PI3K-mediated disorders |
| CA3018429A1 (en) * | 2016-04-22 | 2017-10-26 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 9 (cdk9) by conjugation of cdk9 inhibitors with e3 ligase ligand and methods of use |
| EP3755689B1 (en) * | 2018-02-20 | 2023-12-06 | Dana-Farber Cancer Institute, Inc. | Inhibitors of egfr and methods of use thereof |
-
2019
- 2019-02-20 CA CA3087288A patent/CA3087288A1/en active Pending
- 2019-02-20 WO PCT/US2019/018773 patent/WO2019164948A1/en not_active Ceased
- 2019-02-20 JP JP2020566548A patent/JP2021514400A/ja active Pending
- 2019-02-20 US US16/970,881 patent/US20200390783A1/en not_active Abandoned
- 2019-02-20 EP EP19758285.1A patent/EP3755690A4/en not_active Withdrawn
- 2019-02-20 AU AU2019225806A patent/AU2019225806A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021514400A5 (https=) | ||
| CY1122949T1 (el) | ΠΥΡΑΖΟΛΟ[1,5-a]ΠΥΡΑΖΙΝ-4-ΥΛΟ ΠΑΡΑΓΩΓΑ ΩΣ JAK-ΑΝΑΣΤΟΛΕΙΣ | |
| RU2350605C2 (ru) | Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ | |
| JP2018522879A5 (https=) | ||
| PE20240879A1 (es) | Inhibidor sos1 y uso del mismo | |
| JP2021523221A5 (https=) | ||
| PH12022551014A1 (en) | Substituted tricyclic compounds | |
| JP2021514011A5 (https=) | ||
| JP2016540742A5 (https=) | ||
| JP2020510091A5 (https=) | ||
| JPWO2020243415A5 (https=) | ||
| JP2009536620A5 (https=) | ||
| EA201290260A1 (ru) | Бензимидазол-имидазольные производные | |
| JP2016518437A5 (https=) | ||
| RU2017105781A (ru) | Индазольные соединения в качестве ингибиторов киназы fgfr, их получение и применение | |
| RU2019100164A (ru) | Гетероциклическое соединение, используемое как ингибитор fgfr | |
| JP2018538248A5 (https=) | ||
| JP2014521688A5 (https=) | ||
| JP2010504346A5 (https=) | ||
| JPWO2019164948A5 (https=) | ||
| RU2016137356A (ru) | Соединение нафтиламида, способ его получения и применение | |
| CO2020001326A2 (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
| EA201791816A1 (ru) | Ингибиторы kv1.3 и их применение в медицине | |
| RU2009119181A (ru) | Гетероциклические соединения и их применение в качестве ингибиторов гликогенсинтаза-киназы-3 | |
| JP2019527724A5 (https=) |